Robert Davidson, CEO of CURE Pharmaceutical, a drug delivery and development company discusses their delivery platform called CUREform™, which includes their signature oral film called CUREfilm® and how they were able to figure out RX dosage on thin films. This is a major gain for those who have problems taking traditional pills….especially in a hospital setting. He also talks about the recent Investigational New Drug (IND) approval by the FDA for their ED drug CUREfilmBlue™ and what’s next in the pipeline.
Robert Davidson is CURE’s CEO. Prior to his role at CURE Pharmaceutical, Davidson served as President and CEO of InnoZen, Inc., CEO of Gel Tech LLC, CEO of Bio Delivery Technologies Inc, and served on multiple corporate boards. Mr. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Chloraseptic, Suppress as well as Pedistrips, a private label electrolyte oral thin film sold in major drug store chains. Mr. Davidson received his B.S. degree with a concentration in Biological Life Sciences. He has a Master’s Certificate in Applied Project Management from Villanova University, Masters of Public Health and Wellness from American Military University in Virginia and a Masters in Health and Wellness from Liberty University in Virginia. Davidson also completed his Post Graduate Studies at the University of Cambridge with a letter of commendation.